研究单位：[1]Jiangsu Gensciences lnc.[2]Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.[3]Beijing tongren hospital,CMU,Beijing,China[4]XiangYa Hospital CentralSouth University,Changsha,China[5]The Second Affiliated Hospital of Chongqing Medical University,Chongqing,China[6]Fujian Medical University Union Hospital,Fuzhou,China[7]Nanfang Hospital of Southern Medical University,Guangzhou,China[8]The First Affiliated Hospital，Zhejiang University School of Medicine,Hangzhou,China[9]Anhui Provincial Hospital,Hefei,China[10]Jinan central hospital,Jinan,China[11]The First Affiliated Hospital of Shandong First Medical University,Jinan,China[12]The Second Affiliated Hospital of Kunming Medical University,Kunming,China[13]The First Hospital of Lanzhou University,Lanzhou,China[14]Jiangxi Provincial People's Hospital,Nanchang,China[15]Nanjing Drum Tower Hospital,Nanjing,China[16]Affiliated Hospital of Nantong University,Nantong,China[17]The Affiliated Hospital of Qingdao University,Qingdao,China[18]Ruijin Hospital, Shanghai Jiaotong University School Of Medicine,Shanghai,China[19]Shenzhen Second People's Hospital,Shenzhen,China[20]The First Affiliated Hospital of Soochow University,Suzhou,China[21]The Second Hospital of Shanxi Medical University,Taiyuan,China[22]North China University of Science and Technology Affiliated Hospital,Tangshan,China[23]Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin,China[24]Affiliated Hospital of Jiangnan University,Wuxi,China[25]The First Affiliated Hospital of Xiamen University,Xiamen,China[26]Zhenyu Li,Xuzhou,China[27]Subei People's Hospital of Jiangsu province,Yangzhou,China[28]Henan Cancer Hospital,Zhengzhou,China[29]Henan Provincial People's Hospital,Zhengzhou,China[30]Zhengzhou People's Hospital,Zhengzhou,China
To evaluate the prophylactic efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. To evaluate the safety of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. Secondary purpose: To evaluate the efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein for injection (FRSW117) in hemostasis and surgical hemostasis in patients with severe hemophilia A. To evaluate the pharmacokinetic (PK) characteristics of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A. To evaluate the immunogenicity of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A.
